The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Schreiber H, Penner I-K, Maier T, Hieke-Schulz S, Leemhuis J, Ziemssen T.
Verlag
Publisher-Information
Journal of Central Nervous System Disease. 2024;16.
Link
Zur Publikation (externer Server)
https://doi.org/10.1177/11795735241296001
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
MSZ
Treatments
2024
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
MS Treatments
Jahr
2025
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis
MASC
Jahr
2025
Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment
Mobility
Jahr
2025
A roadmap for safe, regulation-compliant Living Labs for AI and digital health development
MASC
Jahr
2025
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
MASC
Jahr
2025